Gut microbes play important roles in human health, but most of them are hard to be grown outside the human body, which makes studying their functions very challenging. Petri Bio is developing the technology to turn this hard to get resource into a valuable drug discovery platform. The human gut microbiome alone synthesizes over 2 million unique and previously unstudied compounds that interact with our bodies. As the founders mentioned “By directly analyzing genomic data encoding the compounds, we have created a library of thousands of the most promising of these bioactive compounds, and currently developing a high throughput screening method to identify therapeutic lead candidates from it.” They are currently targeting chronic diseases such as IBD and NASH (fatty liver disease).
As an early-stage startup, Petri Bio is raising a pre-seed round and is currently running a crowdfunding campaign on Wefunder: wefunder.com. This round of funding would be used to further develop lab-based proof-of-concept and establish patent portfolio.
Key Features:
– Developing therapeutics and healthcare products informed by the data collected by microbial genome projects;
– Positioned to mine 32+ terabytes of genomic data for future drug precursors.
– Early pipeline of candidates help treat IBD, which affects 1.6M people and $15B market;
– Drug precursor for the treatment of NAFLD/NASH (“fatty liver disease”), $7B growing market;
– Working with Startup Legal Garage, an innovative program founded by UC Hastings Law School now partnering with QB3, for legal support to strengthen defensibility;
– Founded by 2 PhD scientists (3 patents and 14 publications). 2nd-time founder (YCS17)
Click here to learn more about their technology
Company Name: Petri Bio, Inc
Company Website: petribio.com
Company LinkedIn Page: www.linkedin.com
Location of Headquarter: Los Angeles
Biocom Member since: 2019
Campaign profile: wefunder.com
They are looking for: Feedback and funding
